Whale Analyzer
Perceptive Advisors 13F Holdings and Portfolio Changes
Perceptive Advisors reported $6.66B in 13F securities for Q2 2026, with 109 positions. Values are as of the report date; option positions, when present, use underlying-security values. This is not complete fund assets or investment performance.
Open interactive portfolioLatest 13F portfolio changes
New or increased positions include SPYRE THERAPEUTICS (SYRE), CELCUITY (CELC), ASCENDIS PHARMA A/S (ASND), and RHYTHM PHARMACEUTICALS (RYTM). Reduced or exited positions include ASCENDIS PHARMA A/S (ASND), ROIVANT SCIENCES (ROIV), TRAVERE THERAPEUTICS (TVTX), and CENTESSA PHARMACEUTICALS (CNTA). These are comparisons between reported positions, not a record of execution dates, prices or cash traded.
Latest filing metadata: quarter Q2 2026; report date 2026-06-30; filing date 2026-08-14; disclosure source SEC 13F.
Reported holdings and concentration
Perceptive Advisors's Q2 2026 13F report contains 109 positions valued at $6.66B. The largest reported holdings include PRAXIS PRECISION MEDICINES I, SPYRE THERAPEUTICS, CELCUITY, ASCENDIS PHARMA A/S, and RHYTHM PHARMACEUTICALS.
The three largest positions in the holdings table account for approximately 21.7% of reported 13F value. The largest reported sector exposure is Health Care at 70.3% of the disclosed portfolio.
The filing metadata lists report date 2026-06-30, filing date 2026-08-14, SEC accession 0001012975-26-000777. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
Perceptive Advisors portfolio analytics
the top five positions account for 31.0% of disclosed value; the largest sector exposure is Health Care at 70.3%; latest prices differ from modeled cost estimates by an average 147.9% across 100 tracked positions (estimated costs, not reported purchase prices or actual investment returns).
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| PRAX whale holders PRAXIS PRECISION MEDICINES I | $681.6M | 10.6% | Held |
| SYRE whale holders SPYRE THERAPEUTICS INC | $383.5M | 6.0% | Increased |
| CELC whale holders CELCUITY INC | $334.5M | 5.2% | Increased |
| ASND whale holders ASCENDIS PHARMA A/S | $310.4M | 4.8% | New |
| RYTM whale holders RHYTHM PHARMACEUTICALS INC | $287.2M | 4.5% | Increased |
| ROIV whale holders ROIVANT SCIENCES LTD | $286.1M | 4.4% | Reduced |
| RLAY whale holders RELAY THERAPEUTICS INC | $263.9M | 4.1% | Increased |
| TVTX whale holders TRAVERE THERAPEUTICS INC | $213.2M | 3.3% | Reduced |
| KARD whale holders KARDIGAN INC | $195.6M | 3.0% | New |
| NUVL whale holders NUVALENT INC | $195.2M | 3.0% | Held |
New and increased positions
Largest reported position values among additions; not amounts spent buying.
- SYRE whale holders — SPYRE THERAPEUTICS INC ($383.5M)
- CELC whale holders — CELCUITY INC ($334.5M)
- ASND whale holders — ASCENDIS PHARMA A/S ($310.4M)
- RYTM whale holders — RHYTHM PHARMACEUTICALS INC ($287.2M)
- RLAY whale holders — RELAY THERAPEUTICS INC ($263.9M)
- KARD whale holders — KARDIGAN INC ($195.6M)
Reduced and exited positions
Sorted by reported position value; exits use the prior report. These are not sale proceeds.
- ASND whale holders — ASCENDIS PHARMA A/S ($350.3M)
- ROIV whale holders — ROIVANT SCIENCES LTD ($286.1M)
- TVTX whale holders — TRAVERE THERAPEUTICS INC ($213.2M)
- CNTA whale holders — CENTESSA PHARMACEUTICALS PLC ($208.9M)
- EWTX whale holders — EDGEWISE THERAPEUTICS INC ($177.7M)
- APGE whale holders — APOGEE THERAPEUTICS INC ($173.6M)
Allocation
- Health Care: 70.3%
- Other: 28.7%
- Information Technology: 0.9%
Data notes
Report date: 2026-06-30
Disclosure source: SEC 13F
Read the original SEC filing (0001012975-26-000777)
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
- Elliott Investment Management 13F holdings and portfolio changes — Elliott Investment Management
- Pabrai Investment Funds 13F holdings and portfolio changes — Pabrai Investment Funds
- OrbiMed Advisors 13F holdings and portfolio changes — OrbiMed Advisors
- Paulson & Co 13F holdings and portfolio changes — Paulson & Co
- HongShan (Sequoia China) 13F holdings and portfolio changes — HongShan (Sequoia China)
- RA Capital Management 13F holdings and portfolio changes — RA Capital Management
- Baker Bros. Advisors 13F holdings and portfolio changes — Baker Bros. Advisors
- Alpine Associates Management 13F holdings and portfolio changes — Alpine Associates Management
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Questions about this 13F filing
What does Perceptive Advisors report for Q2 2026?
The filing reports 109 positions and $6.66B in 13F securities. The holdings table shows reported values and weights; option values follow the filing's reporting conventions.
What changed between filings?
New or increased positions include SPYRE THERAPEUTICS (SYRE), CELCUITY (CELC), ASCENDIS PHARMA A/S (ASND), and RHYTHM PHARMACEUTICALS (RYTM). Reduced or exited positions include ASCENDIS PHARMA A/S (ASND), ROIVANT SCIENCES (ROIV), TRAVERE THERAPEUTICS (TVTX), and CENTESSA PHARMACEUTICALS (CNTA).
Do these amounts show how much was bought or sold?
No. The change lists are ranked by reported position value. Exited positions use their value in the prior report. These amounts are not execution prices, cash invested or sale proceeds.
Is this the current portfolio?
No. Form 13F is a quarter-end snapshot, generally filed within 45 days of quarter end. It excludes short positions and does not cover every asset. Compare the report date and filing date before using the data.